title: Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA).
  
  
  METHODS
  Adults (n=583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting.
  
  
  RESULTS
  All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo.
  
  
  CONCLUSIONS
  Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.
authors.affiliation: Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. tjs@northwestern.edu
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Schnitzer
authors.forename: Jannie
authors.initials: J
authors.lastname: Beier
authors.forename: Piet
authors.initials: P
authors.lastname: Geusens
authors.forename: Paul
authors.initials: P
authors.lastname: Hasler
authors.forename: Sanjay K
authors.initials: SK
authors.lastname: Patel
authors.forename: Ingo
authors.initials: I
authors.lastname: Senftleber
authors.forename: Xavier
authors.initials: X
authors.lastname: Gitton
authors.forename: Alan
authors.initials: A
authors.lastname: Moore
authors.forename: Victor S
authors.initials: VS
authors.lastname: Sloan
authors.forename: Gyula
authors.initials: G
authors.lastname: Poór
mesh_terms: D000368:Aged; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D004008:Diclofenac / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D004311:Double-Blind Method; D005260:Female; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D009930:Organic Chemicals / Q000008:administration & dosage* / Q000009:adverse effects; D015207:Osteoarthritis, Hip / Q000188:drug therapy* / Q000503:physiopathology; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000503:physiopathology; D010146:Pain / Q000188:drug therapy; D010919:Placebos; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D009930:Organic Chemicals; D010919:Placebos; D004008:Diclofenac; C473384:lumiracoxib